these were described as constipation, excessive abdominal cramping, bloating, upper gi events, gi disease, gi symptoms, and severe diarrhoea or abdominal pain (calcium 14.1%, placebo 10.0%), relative risk (rr) 1.43 95% confidence interval (ci) 1.28 to 1.59, p < 0.001.